74%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
74%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
74%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
74%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
English (International)
N Nanobiotix
N
Open
2.75 -4.68
Overview
Share price change
24h
Min
2.76
Max
2.935
Income | -22M |
|---|---|
Sales | 9.3M |
Profit margin | -235.461 |
Employees | 108 |
EBITDA | -23M |
Recommendations | Buy |
|---|---|
12 Months Forecast | +342.18% upside |
Next Earnings | 21 May 2025 |
|---|
Market Cap | 142M |
|---|---|
Previous open | 7.43 |
Previous close | 2.75 |
Technical Score
By Trading Central
Confidence
Bullish Evidence
Nanobiotix Chart
Past performance is not a reliable indicator of future results.
Related News
Peer Comparison
Price change
Nanobiotix Forecast
Price Target
By TipRanks
342.18% upside
12 Months Forecast
Average 13 EUR 342.18%
High 16 EUR
Low 10 EUR
Based on 2 Wall Street analysts offering 12 month price targets forNanobiotix - Dist in the last 3 months.
Financials
Selling and administration expenses
Operating expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
Interest expense on debt
EBITDA
Operating profit
$
About Nanobiotix
Nanobiotix S.A., a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer. The company has a partnership with Lian Oncology Limited to develop and commercialize NBTXR3 in Greater China, South Korea, Singapore, and Thailand. Nanobiotix S.A. was incorporated in 2003 and is headquartered in Paris, France.
